Disc Medicine rallies $90m Series B

Disc Medicine, a developer of treatments for serious and debilitating hematologic diseases, has raised $90 million in Series B financing.

Disc Medicine, a developer of treatments for serious and debilitating hematologic diseases, has raised $90 million in Series B financing. OrbiMed led the round with participation from other backers that included Arix Bioscience, Janus Henderson Investors, 5AM Ventures, Rock Springs Capital, Nantahala Capital Management and Willett Advisors.

Source: Press Release